TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01598467

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic assisted sacrocolpopexy (RASC)
Description: Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
Study: NCT02234804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime Stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience Prime Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Resolute Integrity stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Resolute Integrity stent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Study: NCT03722641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 1: Milk
Description: Developed reference product based on milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 1: Milk
Description: Developed reference product based on milk

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat
Study: NCT03804866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study: NCT02936258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Targeted Biopsy
Description: Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
Study: NCT03722641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product
Study: NCT03013543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection
Study: NCT00265824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, erlotinib
Description: bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
Study: NCT03224702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6495
Description: Subjects will receive M6495 on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matched to M6495 on Day 1
Study: NCT03722641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product
Study: NCT01700894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program + Motivational Interviewing Calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program + Automated Calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program
Study: NCT02267421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based Aerobic exercise training
Study: NCT03165851

Intervention type: OTHER
Intervention: Risk-stratified therapy
Description: Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
Study: NCT04178330

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
Study: NCT03343665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg in 4 ml Injection
Description: 40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
Study: NCT01326312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 1000mg
Description: comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot
Description: comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 2000mg
Description: comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
Study: NCT03164967

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bivigam
Study: NCT04382911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoroestradiol
Description: Patients will receive the FES tracer during a PET/MRI scan
Study: NCT02394080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Bone Stabilization System
Description: Treatment of acute humerus fractures
Study: NCT02234804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Study: NCT02583854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RY-STOP hemostasis device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR-Band, Terumo
Study: NCT01733758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Description: Albiglutide will be available as a pen injector that delivers 30mg of albiglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg weekly
Description: Albiglutide will be available as a pen injector that delivers 50mg of albiglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Albiglutide matching placebo will be available as a pen injector

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Albiglutide matching placebo will be available as a pen injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 0.9 mg daily
Description: Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
Study: NCT01558466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diluent
Description: The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
Study: NCT03215134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-criticism intervention
Description: Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
Study: NCT05581316

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.
Description: This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.
Description: This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
Study: NCT03770429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
Study: NCT02765204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study: NCT00990366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook´s biliary stent with an antireflux stent, normal biliary stent
Description: arms are assigned randomly by closed envelope method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook´s biliary stent with an antireflux stent, normal biliary stent
Description: arms are assigned randomly by closed envelope method
Study: NCT00382434

Intervention type: PROCEDURE
Intervention: presence of an emergency pharmacist in the ED
Study: NCT03769038

Intervention type: DEVICE
Group type: OTHER
Intervention: chronic total occlusion
Description: chronic total occlusion of coronary atery was opened and then stents were placed
Study: NCT00558116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Description: The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Dynamic splinting
Description: The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
Study: NCT03489889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid 300mg tablet
Description: Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid 300mg capsule
Description: Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
Study: NCT03315039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
Study: NCT04387812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrodes home PSG system
Description: Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
Study: NCT00696332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: capsules Talampanel, 3 times per day, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: capsules Talampanel, 3 times per day, 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, placebo, 3 times a day, for 52 weeks
Study: NCT04100759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg Oral Tablet
Description: Sildenafil 50 mg Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg Oral Tablet
Description: Sildenafil 50 mg Oral Tablet
Study: NCT04120961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolonged continuous use of bivalirudin
Description: prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)

Intervention type: DRUG
Group type: OTHER
Intervention: bivalirudin use during ePCI
Description: bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
Study: NCT00894868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of vildagliptin
Study: NCT02336672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryothermal ablation
Description: Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
Study: NCT03187444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Examinations
Description: Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
Study: NCT05318404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jejunostomy feeding
Description: Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
Study: NCT03101501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
Study: NCT02703324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT04381169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
Study: NCT04381663

Intervention type: PROCEDURE
Intervention: conservative treatment
Description: conservative treatment for patients with cervical spine stenosis without myelopathy

Intervention type: PROCEDURE
Intervention: surgical treatment
Description: surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
Study: NCT04910035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises Training
Description: SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
Study: NCT03492541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol-based eye drops
Description: Nano-emulsion ocular lubricant
Study: NCT02708810

Intervention type: DEVICE
Group type: OTHER
Intervention: Unframed Virtual Cone
Description: A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.

Intervention type: RADIATION
Group type: OTHER
Intervention: 80 Gy Radiation
Study: NCT01436786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
Study: NCT00003515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00856765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon
Description: Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare metal stent
Description: Bare metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Bare metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting stent
Description: Paclitaxel eluting stent
Study: NCT00894361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA surgery with the rotating platform mobile-bearing knee design
Description: Depuy Sigma RP rotating platform design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA surgery with the all-polyethylene tibia knee design
Description: Depuy Sigma fixed-bearing design with all-polyethylene tibia
Study: NCT02765204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study: NCT04100759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg Oral Tablet
Description: Sildenafil 50 mg Oral Tablet
Study: NCT02813239

Intervention type: OTHER
Intervention: hCG
Description: Oocyte maturation with hCG